Abogen positions itself as the world's first validated provider of saliva-based diagnostics for research and laboratory applications. The company's competitive advantage lies in its proprietary technology platform and third-party validated results, targeting the massive diagnostic sampling market with a less invasive, more patient-friendly approach.
Cyborg Score Rationale
The company has proven core technology and early market validation through research partnerships, but faces challenges with minimal scale (2-10 employees), very limited funding history (~$1.3M to $1.6M raised), and stalled fundraising momentum since 2017. No recent publicly documented developments or commercial traction are evident.
Top Insights
Pioneered saliva-based diagnostic extraction validated by independent third parties, addressing patient comfort and safety in clinical sampling
Minimal capitalization and employee count suggest nascent stage with bootstrap or angel-dependent funding model
Products currently deployed only in research and lab settings; no clinical or consumer market presence documented
Long dormancy in fundraising activity (last documented round in 2017) raises questions about ongoing operations and strategic direction
Named Competitors
At-home blood testing — Leading clinical laboratory services and at-home test kits
OralDNA Labs — Salivary diagnostics for healthcare providers specializing in oral health testing
Salignostics — Saliva-based diagnostics platform with pregnancy testing, biomarker detection, and point-of-care solutions
OrisDX — Saliva-based molecular diagnostics for early detection of oral and head-neck cancers